FDA approves new Pfizer biosimilar
Pfizer announced the FDA has approved IXIFI™ (PF-06438179, infliximab-qbtx), a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product. December 13, 2017